scholarly journals K-rasMutational Status in Cytohistological Tissue as a Molecular Marker for the Diagnosis of Pancreatic Cancer: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Jing Yang ◽  
Jingjing Li ◽  
Rong Zhu ◽  
Huawei Zhang ◽  
Yuanyuan Zheng ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Diagnostic Accuracy ◽  
Test Performance ◽  
Meta Analysis ◽  
Diagnostic Odds Ratio ◽  
Pancreatic Tissue ◽  
Test Material ◽  
Original Research ◽  
Summary Receiver Operating Characteristic ◽  
Diagnostic Significance

Background. More clinically meaningful diagnostic tests are needed in pancreatic cancer (PC).K-rasmutations are the most frequently acquired genetic alteration.Methods. Original research articles involving the diagnostic accuracy ofK-rasmutation detection in PC were selected. Data were presented as forest plots and summary receiver operating characteristic (SROC) curve analysis was used to summarize the overall test performance.Results. We assessed 19 studies from 16 published articles. The reports were divided into three groups according to the process used to obtain the test material. The summary estimates for detectingK-rasstatus using an invasive method (fine needle aspiration (FNA), endoscopic retrograde cholangiopancreatography (ERCP), or surgery) were better than cytology: the pooled sensitivity was 77% (95% confidence interval (CI): 74–80%) versus 54% (95% CI: 47–61%); specificity was 88% (95% CI: 85–91%) versus 91% (95% CI: 83–96%); and diagnostic odds ratio (DOR) was 20.26 (11.40–36.03) versus 7.52 (95% CI: 2.80–20.18), respectively. When two procedures were combined, the diagnostic accuracy was markedly improved.Conclusions. The analysis ofK-rasmutations in pancreatic tissue has a promising diagnostic significance in PC. Further valuable studies are needed.

Sensitivity and Specificity of Dickkopf-1 Protein in Serum for Diagnosing Hepatocellular Carcinoma: A Meta-Analysis

2014 ◽  
Vol 29 (4) ◽  
pp. 403-410 ◽  
Author(s):  
Jie Zhang ◽  
Ying Zhao ◽  
Qin Yang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Diagnostic Accuracy ◽  
Test Performance ◽  
Meta Analysis ◽  
Diagnostic Odds Ratio ◽  
Likelihood Ratios ◽  
Summary Receiver Operating Characteristic ◽  
Knowledge Infrastructure ◽  
Combined Test ◽  
Dickkopf 1

Objective This meta-analysis evaluated the diagnostic accuracy of positive serum Dickkopf-1 (DKK1) for diagnosing hepatocellular carcinoma (HCC). Material and methods Articles listed on Embase, PubMed, Wanfang, Weipu Periodical Database or the Chinese National Knowledge Infrastructure (CNKI) and published up to July 10, 2013, were searched in either English or Chinese. The pooled sensitivity (SEN), specificity (SPE), positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR) and summary receiver operating characteristic (sROC) curve were calculated to summarize the overall test performance. Results Four articles (6 studies) provided DKK1 diagnostic data. The pooled SEN, SPE, PLR, NLR, DOR and area under the sROC curve of DKK1 for the diagnosis of HCC were 0.65 (95% confidence interval [95% CI], 0.52-0.76), 0.94 (95% CI, 0.82-0.98), 10.1 (95% CI, 3.68-27.74), 0.38 (95% CI, 0.28-0.51), 26.90 (95% CI, 10.45-69.19) and 0.84 (95% CI, 0.81-0.87), respectively. Three articles (5 studies) provided DKK1 and α-fetoprotein (AFP) combined test data. The pooled SEN, SPE, PLR, NLR, DOR and area under the sROC curve of combined detection for the diagnosis of HCC were 0.81 (95% CI, 0.76-0.85), 0.85 (95% CI, 0.78-0.91), 5.52 (95% CI, 3.76-8.10), 0.22 (95% CI, 0.19-0.27), 24.60 (95% CI, 17.69-34.19) and 0.88 (95% CI, 0.85-0.91), respectively. Conclusion Both DKK1 and DKK1 plus AFP had high diagnostic accuracy for diagnosis of HCC.

scholarly journals Meta-Analysis: Urinary Calprotectin for Discrimination of Intrinsic and Prerenal Acute Kidney Injury

2019 ◽  
Vol 8 (1) ◽  
pp. 74 ◽  
Author(s):  
Jia-Jin Chen ◽  
Pei-Chun Fan ◽  
George Kou ◽  
Su-Wei Chang ◽  
Yi-Ting Chen ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Diagnostic Accuracy ◽  
Diagnostic Performance ◽  
Pediatric Population ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Kidney Injury ◽  
Diagnostic Odds Ratio ◽  
Summary Receiver Operating Characteristic ◽  
Significant Difference

Background: Urinary calprotectin is a novel biomarker that distinguishes between intrinsic or prerenal acute kidney injury (AKI) in different studies. However, these studies were based on different populations and different AKI criteria. We evaluated the diagnostic accuracy of urinary calprotectin and compared its diagnostic performance in different AKI criteria and study populations. Method: In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched PubMed, Embase, and the Cochrane database up to September 2018. The diagnostic performance of urinary calprotectin (sensitivity, specificity, predictive ratio, and cutoff point) was extracted and evaluated. Result: This study included six studies with a total of 502 patients. The pooled sensitivity and specificity were 0.90 and 0.93, respectively. The pooled positive likelihood ratio (LR) was 15.15, and the negative LR was 0.11. The symmetric summary receiver operating characteristic (symmetric SROC) with pooled diagnostic accuracy was 0.9667. The relative diagnostic odds ratio (RDOC) of the adult to pediatric population and RDOCs of different acute kidney injury criteria showed no significant difference in their diagnostic accuracy. Conclusion: Urinary calprotectin is a good diagnostic tool for the discrimination of intrinsic and prerenal AKI under careful inspection after exclusion of urinary tract infection and urogenital malignancies. Its performance is not affected by different AKI criteria and adult or pediatric populations.

scholarly journals EUS-Guided FNA for Diagnosis of Pancreatic Cystic Lesions: a Meta-Analysis

2015 ◽  
Vol 36 (3) ◽  
pp. 1197-1209 ◽  
Author(s):  
Qi-Xian Wang ◽  
Jun Xiao ◽  
Matthew Orange ◽  
Hu Zhang ◽  
You-Qing Zhu
Keyword(s):  
Diagnostic Accuracy ◽  
Meta Analysis ◽  
Diagnostic Odds Ratio ◽  
Needle Aspiration ◽  
Cystic Lesions ◽  
Clinical Tool ◽  
Current Standard ◽  
Summary Receiver Operating Characteristic ◽  
Fluid Analysis

Background: Preoperative diagnosis of pancreatic cystic lesions (PCLs) must be reliable as the current standard treatment, major or total pancreatectomy, dramatically affects quality of life. Additionally, early diagnosis of malignancy is essential to an improved prognosis. The diagnostic accuracy of fluid analysis using endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has been demonstrated in pancreatic solid lesions. The utility of this technique in the diagnosis of PCLs is still unknown. Methods: A comprehensive search was performed in multiple databases. Studies differentiating benign and malignant PCLs via EUS-FNA were included in this meta-analysis. The quality of diagnostic accuracy studies (QUADAS) was adopted to evaluate the selected studies. Pooled sensitivity, specificity, likelihood ratio, diagnostic odds ratio, and summary receiver operating characteristic (sROC) curve analyses were conducted. Two main classification types of malignancy were characterized and analyzed. We also generated a subgroup analysis of available clinical factors. Publication bias was evaluated by Begg's and Egger's tests. Results: Sixteen studies containing 1024 subjects have been published. The pooled sensitivity for malignant cytology according to classification 1 was 0.51 (95% CI, 0.45-0.58), and pooled specificity was 0.94 (95% CI, 0.92-0.96). When the detected PCLs were identified as classification 2, suspicious malignancy or potential malignancy, sensitivity and specificity were similar, 0.52 (95% CI, 0.46-0.57) and 0.97 (95% CI, 0.95-0.98) respectively. Conclusion: This meta-analysis demonstrates that EUS-FNA is a reliable clinical tool for the diagnosis of PCLs. However, a more accurate algorithm is needed to reduce various biases and to improve the sensitivity of EUS-FNA in the detection of malignant PCLs.

scholarly journals Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis

2018 ◽  
Vol 11 ◽  
pp. 175628481878557 ◽  
Author(s):  
Yuen Sau Tham ◽  
Diana E. Yung ◽  
Shmuel Fay ◽  
Takayuki Yamamoto ◽  
Shomron Ben-Horin ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Diagnostic Accuracy ◽  
Meta Analysis ◽  
Surrogate Marker ◽  
Diagnostic Odds Ratio ◽  
Fecal Calprotectin ◽  
Ileocecal Resection ◽  
Summary Receiver Operating Characteristic ◽  
Endoscopic Recurrence

Background: Anastomotic recurrence is frequent in patients with Crohn’s disease (CD) following ileocecal resection. The degree of endoscopic recurrence, quantified by the Rutgeerts score (RS), correlates with risk of clinical and surgical recurrence. Several studies demonstrate the accuracy of fecal calprotectin (FC) for detection of endoscopic recurrence, however the optimal threshold FC value remains to be established. The aim of our meta-analysis was to evaluate the accuracy of common FC cut-offs for detection of endoscopic recurrence. Methods: We performed a systematic literature search for studies evaluating postoperative recurrence in CD which reported RS and FC levels. Endoscopic recurrence was defined as RS = 2–4 (or RS ⩾ 2). We calculated pooled diagnostic sensitivity, specificity, diagnostic odds ratio (DOR) and constructed summary receiver operating characteristic (SROC) curves for each available FC cut-off value. Results: A total of 54 studies were retrieved; 9 studies were eligible for analysis. Diagnostic accuracy was calculated for FC values of 50, 100, 150 and 200 µg/g. A significant threshold effect was observed for all FC values. The optimal diagnostic accuracy was obtained for FC value of 150 µg/g, with a pooled sensitivity of 70% [95% confidence interval (CI) 59–81%], specificity 69% (95% CI 61–77%), and DOR 5.92 (95% CI 2.61–12.17). The area under the SROC curve was 0.73. Conclusion: FC is an accurate surrogate marker of postoperative endoscopic recurrence in CD patients. The FC cut-off 150 μg/g appears to have the best overall accuracy. Serial FC evaluations may eliminate or defer the need for colonoscopic evaluation in up to 70% of postoperative CD patients.

scholarly journals Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis

2018 ◽  
Vol 51 (6) ◽  
pp. 2631-2646 ◽  
Author(s):  
Jiangyue Qin ◽  
Ni Zeng ◽  
Ting Yang ◽  
Chun Wan ◽  
Lei Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Diagnostic Accuracy ◽  
Test Performance ◽  
Meta Analysis ◽  
Cyclin B1 ◽  
Diagnostic Value ◽  
Likelihood Ratios ◽  
Summary Receiver Operating Characteristic ◽  
Mixed Effect ◽  
Sensitivity Specificity

Background/Aims: Recently, many studies have demonstrated that various tumor-associated autoantibodies have been detected in early stages of lung cancer. Therefore, we conducted a meta-analysis to comprehensively evaluate available evidence on the diagnostic value of autoantibodies against tumor-associated antigens in lung cancer. Methods: We systematically searched PubMed, Scopus, Web of Science and other databases through 23 March 2018. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2. We used the bivariate mixed-effect models to calculate pooled values of sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, diagnostic odds ratios and associated 95% confidence intervals. Summary receiver operating characteristic (SROC) curves were used to summarize overall test performance. Deek’s funnel plot was used to detect publication bias. Results: Review of 468 candidate articles identified fifty-three articles with a total of 11,515 patients for qualitative review and meta-analysis. Pooled sensitivity, specificity and area under the SROC curve were as follows for tumor-associated autoantibodies against the following proteins: p53, 0.19, 0.98, 0.82; NY-ESO-1, 0.17, 0.98, 0.90; Survivin, 0.19, 0.99, 0.96; c-myc, 0.14, 0.98, 0.45; Cyclin B1, 0.18, 0.98, 0.91; GBU4-5, 0.07, 0.98, 0.91; CAGE, 0.14, 0.98, 0.90; p16, 0.08, 0.97, 0.91; SOX2, 0.14, 0.99, 0.93; and HuD, 0.17, 0.99, 0.82. Conclusion: Each tumor-associated autoantibody on its own showed excellent diagnostic specificity for lung cancer but inadequate sensitivity. Our results suggest that combinations or panels of tumor-associated autoantibodies may provide better sensitivity for diagnosing lung cancer, and the diagnostic accuracy of tumor-associated autoantibodies should be validated in more studies.

scholarly journals Potential Role of MicroRNA-375 as Biomarker in Human Cancers Detection: A Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Jin Yan ◽  
Qiang She ◽  
Xiaoran Shen ◽  
Yifeng Zhang ◽  
Bingtuan Liu ◽  
...  
Keyword(s):  
Test Performance ◽  
Meta Analysis ◽  
Area Under The Curve ◽  
Diagnostic Odds Ratio ◽  
Diagnostic Value ◽  
Circulating Microrna ◽  
Cancer Type ◽  
Analysis Model ◽  
Summary Receiver Operating Characteristic ◽  
Sensitivity Specificity

The association between circulating microRNA-375 (miR-375) expression and cancers has been studied; however, the results are inconsistent. We searched PubMed, Embase, and Web of Science for studies concerning the diagnostic value of miR-375 for cancer. The bivariate meta-analysis model was employed to summarize sensitivity, specificity, and diagnostic odds ratio (DOR) for miR-375 in the diagnosis of cancer. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were also used to check the overall test performance. A total of 645 cancer patients and 421 cancer-free individuals from 12 studies were contained in this meta-analysis. The summary estimates revealed that the pooled sensitivity was 78% (95% confidence interval (CI): 64%–87%), the specificity was 74% (95% CI: 62%–84%), the DOR was 10.04 (95% CI: 6.01–16.77), and the AUC was 0.82 (95% CI: 0.79–0.85). In addition, we found that the diagnostic effect of miR-375 varies according to the race and cancer type. Our data suggest that miR-375 profiling has a potential to be used as a screening test for cancers but the specific race and cancer should be considered. More studies on the diagnostic value of miR-375 for cancer are needed in the future.

scholarly journals Accuracy of Enzyme-Linked Immunosorbent Assays (ELISAs) in Detecting Antibodies againstMycobacterium lepraein Leprosy Patients: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Omar Ariel Espinosa ◽  
Silvana Margarida Benevides Ferreira ◽  
Fabiana Gulin Longhi Palacio ◽  
Denise da Costa Boamorte Cortela ◽  
Eliane Ignotti
Keyword(s):  
Diagnostic Accuracy ◽  
Odds Ratio ◽  
Meta Analysis ◽  
Characteristic Curve ◽  
Diagnostic Odds Ratio ◽  
Cochrane Library ◽  
Likelihood Ratios ◽  
Summary Receiver Operating Characteristic ◽  
Immunosorbent Assays ◽  
Sensitivity Specificity

IgM againstMycobacterium lepraemay be detected by enzyme-linked immunosorbent assays (ELISAs) based on phenolic glycolipid I (PGL-I) or natural disaccharide octyl bovine serum albumin (ND-O-BSA) as antigens, and the IgG response can be detected by an ELISA based on lipid droplet protein 1 (LID-1). The titers of antibodies against these antigens vary with operational classification. The aim of this study was to compare the accuracy of ELISAs involving PGL-I and ND-O-BSA with that involving LID-1. We included studies that analyze multibacillary and paucibacillary leprosy cases and evaluate the diagnostic accuracy of ELISAs based on LID-1 and/or PGL-I or ND-O-BSA as antigens to measure antibody titers againstM. leprae. Studies were found via PubMed, the Virtual Health Library Regional Portal, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Índice Bibliográfico Espanhol de Ciências de Saúde, the Brazilian Society of Dermatology, National Institute for Health and Clinical Excellence, Cochrane Library, Embase (the Elsevier database), and Cumulative Index to Nursing and Allied Health Literature. The Quality Assessment of Diagnostic Accuracy Studies served as a methodological validity tool. Quantitative data were extracted using the Standards for Reporting of Diagnostic Accuracy. Sensitivity, specificity, and a diagnostic odds ratio were calculated, and a hierarchical summary receiver-operating characteristic curve and forest plots were constructed. The protocol register code for this meta-analysis is PROSPERO 2017: CRD42017055983. Nineteen studies were included. ND-O-BSA showed better overall performance in terms of sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio when compared with PGL-I and LID-1. The multibacillary group showed better performance on these parameters (than the paucibacillary group did), at 94%, 99%, 129, 0.05, and 2293, respectively. LID-1 did not provide any advantage regarding the overall estimate of sensitivity in comparison with PGL-I or ND-O-BSA.

scholarly journals Diagnostic Accuracy of FDA Authorized Serology Tests to Detect SARS-CoV-2 Antibodies: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Rajesh Pandey ◽  
Anand Gourishankar
Keyword(s):  
Systematic Review ◽  
Diagnostic Accuracy ◽  
Receiver Operating Characteristic ◽  
Test Performance ◽  
Operating Characteristic ◽  
Meta Analysis ◽  
Time Interval ◽  
Test Accuracy ◽  
Summary Receiver Operating Characteristic ◽  
Receiver Operating

AbstractImportanceSerology tests are diagnostic and complementary to molecular tests during the COVID-19 pandemic.ObjectiveTo evaluate the diagnostic accuracy of FDA authorized serology tests for the detection of SARS-CoV-2 infection.Data sourcesA search of MEDLINE, SCOPUS, CINAHL Plus, and EMBASE up to April 4, 2020, was performed to identify studies using the “COVID 19 testing” and “meta-analysis.” FDA website was accessed for the list of tests for emergency use authorization (EUA).Study SelectionManufacturer reported serology tests published in the FDA website were selected. Two reviewers independently assessed the eligibility of the selected reports.Data extraction and synthesisThe meta-analysis was performed in accordance with the PRISMA guidelines. A bivariate analysis using the “random-effects model” was applied for pooled summary estimates of sensitivity, specificity, and the summary receiver operating characteristic curves.Main outcomes and measuresThe primary outcome was the diagnostic accuracy of the serology test for detecting SARS-CoV-2 infection. Subgroup analysis of the diagnostic accuracy with lag time between symptom onset and testing were studied.ResultsSeven manufacturer listed reports were included. The pooled sensitivity was 87% (95% CI, 78% - 93%), the pooled specificity was 100% (95% CI, 97% - 100%), and the area under the hierarchical summary receiver operating characteristic curve was 0.97. At ≤ 7 days, sensitivity was 44% (95% CI, 21% - 70%), and for 8-14 days, sensitivity was 84% (95% CI, 67 % - 94%).For blood draws ≥ 15 days after the onset of symptoms, sensitivity was 96% (95% CI, 93% - 98%). Heterogeneity was substantial, and the risk of bias was low in this analysis.Conclusions and relevanceFDA authorized serology tests demonstrate high diagnostic accuracy for SARS-CoV-2 infection (certainty of evidence: moderate). There is a wide variation in the test accuracy based on the duration between the onset of symptoms and the tests (certainty of evidence: low).Key– pointsQuestionsWhat is the pooled diagnostic accuracy of FDA authorized serology tests to detect SARS-CoV-2 antibodies?FindingsIn this systematic review and meta-analysis of seven reports from FDA authorized serology tests to detect antibodies against SARS-CoV2 antibodies (3336 patients/ samples) pooled sensitivity was 87%, and pooled specificity was almost 100%. There was a wide variation in test performance based on the duration between the onset of symptoms and the tests.MeaningFDA authorized tests are highly accurate to detect antibodies against SARS-CoV-2 antibodies if tests are performed under a similar condition, as presented in the original report. There is a wide variation in the test performance based on the time interval between the onset of symptoms to the tests.

Accuracy of MRI Diagnosis of Meniscal Tears of the Knee: A Meta-Analysis and Systematic Review

2019 ◽  
Author(s):  
Wei Wang ◽  
Zheng Li ◽  
Hui-Ming Peng ◽  
Yan-Yan Bian ◽  
Ye Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Diagnostic Accuracy ◽  
Meta Analysis ◽  
Area Under The Curve ◽  
Negative Likelihood Ratio ◽  
Diagnostic Odds Ratio ◽  
Diagnostic Value ◽  
Meniscal Tears ◽  
Summary Receiver Operating Characteristic ◽  
Cross Sectional

AbstractThis study aimed to evaluate the overall diagnostic value of magnetic resonance imaging (MRI) in patients with suspected meniscal tears. PubMed, Cochrane, Embase database updated to November 2017 were searched by the index words to identify qualified studies, including prospective cohort studies and cross-sectional studies. Literature was also identified by tracking using reference lists. Heterogeneity of the included studies was reviewed to select proper effects model for pooled weighted sensitivity, specificity, and diagnostic odds ratio (DOR). Summary receiver operating characteristic (SROC) analyses were performed for meniscal tears. A total of 17 studies were involved in this meta-analysis to explore the diagnostic accuracy of MRI for meniscal tears. The global sensitivity and specificity of MRI of meniscal tears were 92.0% (95% confidence interval [CI]: 88.0–95.0%) and 90.0% (95% CI: 85.0–95.0%) in medial meniscal tears, and 80.0% (95% CI: 66.0–89.0%) and 95.0% (95% CI: 91.0–97.0%) in lateral meniscal tears, respectively. Moreover, the global positive and negative likelihood ratio of MRI of meniscal tears were 10.33 (95% CI: 6.04–17.67) and 0.09 (95% CI: 0.05–0.14) in medial meniscal tears; 16.48 (95% CI: 8.81–30.83) and 0.21 (95% CI: 0.12–0.37) in lateral meniscal tears, respectively. The global DOR was 81.69 (95% CI: 37.94–175.91) in medial meniscal tears and 56.59 (95% CI: 22.51–142.28) in lateral meniscal tears. The results of area under the SROC indicated high accuracy in medial meniscal tears (area under the curve [AUC] = 0.97, 95% CI: 0.95–0.98) and lateral meniscal tears (AUC = 0.96, 95% CI: 0.94–0.97). This review presents a systematic review and meta-analysis to evaluate the diagnostic accuracy of MRI of meniscal tears. Moderate-to-strong evidence suggests that MRI appears to be associated with higher diagnostic accuracy for detecting medial and lateral meniscal tears.

scholarly journals Diagnostic Accuracy of the Quidel Sofia Rapid Influenza Fluorescent Immunoassay in Patients with Influenza-like illness: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Jonghoo Lee ◽  
Jae-Uk Song
Keyword(s):  
Diagnostic Accuracy ◽  
Odds Ratio ◽  
Influenza A ◽  
Meta Analysis ◽  
Characteristic Curve ◽  
Diagnostic Odds Ratio ◽  
Influenza B ◽  
Cochrane Central Register ◽  
Summary Receiver Operating Characteristic ◽  
Sensitivity Specificity

Abstract Background: Although the Quidel Sofia rapid influenza fluorescent immunoassay (FIA) is widely used to identify influenza A and B, the diagnostic accuracy of this test remains unclear. We compared the diagnostic performances of this test with reverse transcriptase-polymerase chain reaction.Methods: A systematic literature search was performed using MEDLINE, EMBASE, and the Cochrane Central Register. The sensitivity, specificity, diagnostic odds ratio (DOR), and a hierarchical summary receiver-operating characteristic curve (HSROC) of this test for identifying influenza A and B were pooled using meta-analysis. A sensitivity and subgroup analysis was used to identify potential sources of heterogeneity within the selected studies.Results: We identified seventeen studies comprising 8,334 patients. The pooled sensitivity, specificity, and DOR of the Quidel Sofia rapid influenza FIA to identify influenza A were 0.78 (95% CI, 0.71–0.83), 0.99 (95% CI, 0.98–0.99), and 251.26 (95% CI, 139.39–452.89), respectively. The pooled sensitivity, specificity, and diagnostic odds ratio of this test to identify influenza B were 0.72 (95% CI, 0.60–0.82), 0.98 (95% CI, 0.96-0.99), and 140.20 (95% CI, 55.92-351.54), respectively. The area under the HSROC for this test was similar for identification of influenza A and influenza B. Age was considered a probable source of heterogeneity.Conclusions: The pooled sensitivities of the Quidel Sofia rapid influenza FIA did not quite meet the target level (≥80%) for both influenza A and B. The interpretation of data should be carefully considered due to substantial between-study heterogeneity.

Sign in / Sign up

Export Citation Format

Share Document